Novavax (NVAX) EBIT (QoQ) (2010 - 2026)
Powered by 
Analysis
Novavax (NVAX) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Novavax | 1.67 Bn | 950.86 Mn | 42.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -255.84% |
| Mar 31, 2026 | -208.43% |
| Dec 31, 2025 | 107.99% |
| Sep 30, 2025 | -276.13% |
| Jun 30, 2025 | -80.39% |
| Mar 31, 2025 | 493.28% |
| Dec 31, 2024 | 2.19% |
| Sep 30, 2024 | -183.24% |
| Jun 30, 2024 | 211.16% |
| Mar 31, 2024 | 21.10% |
| Dec 31, 2023 | -46.12% |
| Sep 30, 2023 | -326.54% |
| Jun 30, 2023 | 117.73% |
| Mar 31, 2023 | -28.25% |
| Dec 31, 2022 | -91.75% |
| Sep 30, 2022 | 73.66% |
| Jun 30, 2022 | -330.76% |
| Mar 31, 2022 | 125.37% |
| Dec 31, 2021 | -168.59% |
| Sep 30, 2021 | 11.19% |